title: Platelet function testing in patients with acute coronary syndrome.
abstract: In patients with an acute coronary syndrome (ACS), inhibition of the platelet P2Y12 receptor is standard of care. The shortcomings of the most commonly used P2Y12 receptor inhibitor clopidogrel-that is its delayed onset of action, its interindividual response variability, and the phenomenon of high on-treatment platelet reactivity-led to the development of more potent P2Y12 receptor inhibitors (prasugrel and ticagrelor) that proved their superiority in terms of reducing thrombotic events compared to clopidogrel. Available randomized studies that aimed at investigating the value of a personalized antiplatelet treatment regimen based on platelet function monitoring results were negative with regard to the possible benefits of monitoring but were all limited by mainly enrolling elective and stable patients with coronary artery disease. Thus, it still warrants further investigation if a tailored, platelet function guided, antiplatelet therapy in ACS patients with the available P2Y12 receptor inhibitors prasugrel, ticagrelor, and clopidogrel can lead to improved patients outcome.
authors: Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Campus Grosshadern, Marchioninistr. 15, 81377 Munich, Germany. MartinOrban@gmail.com
authors: Martin
authors: M
authors: Orban
authors: Dirk
authors: D
authors: Sibbing
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000980:Antiplatyhelmintic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D018579:Patient Selection; D010979:Platelet Function Tests; D057285:Precision Medicine; D011237:Predictive Value of Tests; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D058925:Receptors, Purinergic P2Y12 / Q000097:blood / Q000187:drug effects*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000980:Antiplatyhelmintic Agents; C548576:P2RY12 protein, human; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12
references: Heart. 2001 Jan;85(1):92-3
references: 11119474
references: JAMA. 2011 Sep 21;306(11):1215-23
references: 21934054
references: Circulation. 2004 Jun 29;109(25):3171-5
references: 15184279
references: Thromb Haemost. 2012 Feb;107(2):338-45
references: 22186910
references: J Am Coll Cardiol. 2012 Jul 17;60(3):193-9
references: 22789884
references: J Thromb Haemost. 2007 Aug;5(8):1630-6
references: 17488353
references: Thromb Haemost. 2007 Feb;97(2):282-7
references: 17264958
references: JAMA. 2010 Feb 24;303(8):754-62
references: 20179285
references: N Engl J Med. 2009 Sep 10;361(11):1045-57
references: 19717846
references: J Am Coll Cardiol. 2009 Mar 10;53(10):849-56
references: 19264241
references: Thromb Haemost. 2007 Oct;98(4):838-43
references: 17938809
references: J Am Coll Cardiol. 2012 Jul 31;60(5):369-77
references: 22682553
references: J Am Coll Cardiol. 2011 May 10;57(19):e215-367
references: 21545940
references: J Am Coll Cardiol. 2007 Oct 16;50(16):1541-7
references: 17936152
references: EuroIntervention. 2009 Aug;5(3):325-9
references: 19736156
references: Catheter Cardiovasc Interv. 2003 Jul;59(3):295-302
references: 12822144
references: Circulation. 2003 Jun 17;107(23):2908-13
references: 12796140
references: Am J Cardiol. 2009 Mar 15;103(6):806-11
references: 19268736
references: J Am Coll Cardiol. 2010 Sep 14;56(12):919-33
references: 20828644
references: Dtsch Arztebl Int. 2012 May;109(19):343-51
references: 22675405
references: J Thromb Haemost. 2012 Oct;10(10):1999-2005
references: 22863374
references: Circulation. 2009 Jan 20;119(2):237-42
references: 19118249
references: Circulation. 2009 Dec 1;120(22):2214-21
references: 19917884
references: J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50
references: 17084243
references: N Engl J Med. 2011 Nov 24;365(21):1980-9
references: 22077909
references: J Thromb Haemost. 2006 Mar;4(3):542-9
references: 16371119
references: N Engl J Med. 2012 Nov 29;367(22):2100-9
references: 23121439
references: J Clin Pharmacol. 2009 Aug;49(8):984-98
references: 19546250
references: Eur Heart J. 2008 Apr;29(8):992-1000
references: 18263931
references: J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7
references: 17572245
references: J Am Coll Cardiol. 2005 Nov 15;46(10):1820-6
references: 16286165
references: Catheter Cardiovasc Interv. 2010 Feb 1;75(2):158-66
references: 19902490
references: Heart. 2008 Jun;94(6):743-7
references: 17567647
references: Am J Cardiol. 2012 Jan 15;109(2):214-8
references: 21996146
references: Thromb Haemost. 2011 Sep;106(3):555-8
references: 21725582
references: J Am Coll Cardiol. 2005 Jan 18;45(2):246-51
references: 15653023
references: J Thromb Haemost. 2010 Feb;8(2):250-6
references: 19943882
references: JACC Cardiovasc Interv. 2012 Dec;5(12):1280-7
references: 23257377
references: N Engl J Med. 2007 Nov 15;357(20):2001-15
references: 17982182
references: J Am Coll Cardiol. 2008 Aug 26;52(9):734-9
references: 18718420
references: Handb Exp Pharmacol. 2012;(210):111-33
references: 22918729
references: J Am Coll Cardiol. 2012 Jun 12;59(24):2159-64
references: 22520250
references: J Am Coll Cardiol. 2011 Nov 1;58(19):1945-54
references: 22032704
references: Eur Heart J. 2011 Dec;32(23):2999-3054
references: 21873419
references: Thromb Haemost. 2013 Mar;109(3):517-24
references: 23328965
references: Circ Cardiovasc Interv. 2012 Dec;5(6):797-804
references: 23169985
references: Platelets. 2012;23(5):395-8
references: 22671583
references: J Am Coll Cardiol. 2011 Jun 21;57(25):2474-83
references: 21679849
references: Eur Heart J. 2010 Jan;31(2):227-35
references: 19854728
references: Thromb Haemost. 2010 Apr;103(4):841-8
references: 20135063
references: J Am Coll Cardiol. 2011 Jul 26;58(5):467-73
references: 21777742